Literature DB >> 20673128

Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia.

René Gysin1, Rudolf Kraftsik, Olivier Boulat, Pierre Bovet, Philippe Conus, Emily Comte-Krieger, Andrea Polari, Pascal Steullet, Martin Preisig, Tanja Teichmann, Michel Cuénod, Kim Q Do.   

Abstract

Genetic studies have shown an association between schizophrenia and a GAG trinucleotide repeat (TNR) polymorphism in the catalytic subunit (GCLC) of the glutamate cysteine ligase (GCL), the key enzyme for glutathione (GSH) synthesis. The present study was aimed at analyzing the influence of a GSH dysregulation of genetic origin on plasma thiols (total cysteine, homocysteine, and cysteine-glycine) and other free amino acid levels as well as fibroblast cultures GSH levels. Plasma thiols levels were also compared between patients and controls. As compared with patients with a low-risk GCLC GAG TNR genotype, patients with a high-risk genotype, having an impaired GSH synthesis, displayed a decrease of fibroblast GSH and plasma total cysteine levels, and an increase of the oxidized form of cysteine (cystine) content. Increased levels of plasma free serine, glutamine, citrulline, and arginine were also observed in the high-risk genotype. Taken together, the high-risk genotypes were associated with a subgroup of schizophrenia characterized by altered plasma thiols and free amino acid levels that reflect a dysregulation of redox control and an increased susceptibility to oxidative stress. This altered pattern potentially contributes to the development of a biomarker profile useful for early diagnosis and monitoring the effectiveness of novel drugs targeting redox dysregulation in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673128     DOI: 10.1089/ars.2010.3463

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  27 in total

1.  Oxidative stress in schizophrenia: pathogenetic and therapeutic implications.

Authors:  Jeffrey K Yao; Ravinder Reddy
Journal:  Antioxid Redox Signal       Date:  2011-05-04       Impact factor: 8.401

2.  Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients.

Authors:  A Monin; P S Baumann; A Griffa; L Xin; R Mekle; M Fournier; C Butticaz; M Klaey; J H Cabungcal; P Steullet; C Ferrari; M Cuenod; R Gruetter; J P Thiran; P Hagmann; P Conus; K Q Do
Journal:  Mol Psychiatry       Date:  2014-08-26       Impact factor: 15.992

Review 3.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 4.  Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology.

Authors:  Paul L Wood
Journal:  Neuropsychopharmacology       Date:  2013-07-11       Impact factor: 7.853

5.  Impaired metabolic reactivity to oxidative stress in early psychosis patients.

Authors:  Margot Fournier; Carina Ferrari; Philipp S Baumann; Andrea Polari; Aline Monin; Tanja Bellier-Teichmann; Jacob Wulff; Kirk L Pappan; Michel Cuenod; Philippe Conus; Kim Q Do
Journal:  Schizophr Bull       Date:  2014-03-31       Impact factor: 9.306

Review 6.  Potential Roles of Redox Dysregulation in the Development of Schizophrenia.

Authors:  Diana O Perkins; Clark D Jeffries; Kim Q Do
Journal:  Biol Psychiatry       Date:  2020-04-02       Impact factor: 13.382

Review 7.  Human dermal fibroblasts in psychiatry research.

Authors:  S Kálmán; K A Garbett; Z Janka; K Mirnics
Journal:  Neuroscience       Date:  2016-02-09       Impact factor: 3.590

8.  Genetic Polymorphism Associated Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early Psychosis.

Authors:  Lijing Xin; Ralf Mekle; Margot Fournier; Philipp S Baumann; Carina Ferrari; Luis Alameda; Raoul Jenni; Huanxiang Lu; Benoit Schaller; Michel Cuenod; Philippe Conus; Rolf Gruetter; Kim Q Do
Journal:  Schizophr Bull       Date:  2016-04-11       Impact factor: 9.306

9.  Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.

Authors:  Daniel C Javitt
Journal:  Curr Treat Options Psychiatry       Date:  2015-06

Review 10.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?

Authors:  P Steullet; J H Cabungcal; A Monin; D Dwir; P O'Donnell; M Cuenod; K Q Do
Journal:  Schizophr Res       Date:  2014-07-05       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.